Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Synergistic antitumor activity of lenalidomide with the BET bromodomain inhibitor CPI203 in bortezomib-resistant mantle cell lymphoma

Published:2014-03-18 Issue:10 Volume:28 Page:2049-2059
ISSN:0887-6924
Container-title:Leukemia
language:en
Short-container-title:Leukemia

Author:

Moros A,Rodríguez V,Saborit-Villarroya I,Montraveta A,Balsas P,Sandy P,Martínez A,Wiestner A,Normant E,Campo E,Pérez-Galán P,Colomer D,Roué G

Publisher

Springer Science and Business Media LLC

Subject

Oncology,Cancer Research,Hematology

Link

http://www.nature.com/articles/leu2014106.pdf

Reference40 articles.

1. Jares P, Colomer D, Campo E . Molecular pathogenesis of mantle cell lymphoma. J Clin Invest 2012; 122: 3416–3423.

2. Perez-Galan P, Dreyling M, Wiestner A . Mantle cell lymphoma: biology, pathogenesis, and the molecular basis of treatment in the genomic era. Blood 2011; 117: 26–38.

3. Orlowski RZ, Kuhn DJ . Proteasome inhibitors in cancer therapy: lessons from the first decade. Clin Cancer Res 2008; 14: 1649–1657.

4. Xolalpa W, Perez-Galan P, Rodriguez MS, Roue G . Targeting the ubiquitin proteasome system: beyond proteasome inhibition. Curr Pharm Des 2013; 19: 4053–4093.

5. Fisher RI, Bernstein SH, Kahl BS, Djulbegovic B, Robertson MJ, de VS et al. Multicenter phase II study of bortezomib in patients with relapsed or refractory mantle cell lymphoma. J Clin Oncol 2006; 24: 4867–4874.

Cited by 89 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. BET Bromodomain Inhibitors as an Emerging Class of Anticancer Agents;Handbook of Cancer and Immunology;2023-11-08

2. Targeting the epigenetic reader “BET” as a therapeutic strategy for cancer;Bioorganic Chemistry;2023-11

3. Long non coding RNAs reveal important pathways in childhood asthma: a future perspective;Journal of Molecular Histology;2023-08

4. Targeting bromodomain-containing proteins: research advances of drug discovery;Molecular Biomedicine;2023-05-05

5. Exploiting the ubiquitin system in myeloid malignancies. From basic research to drug discovery in MDS and AML;Blood Reviews;2022-11

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3